Velpatasvir CAS 1377049 84 7 GMP DMF C49H54N8O8 Molecular Formula

Velpatasvir CAS : 1377049-84-7 GMP DMF

Name : Velpatasvir

Chemical Name : Methyl { ( 2S ) - 1 - [ ( 2S , 5S ) - 2 - ( 9 - { 2 - [ ( 2S , 4S ) - 1 - { ( 2R ) - 2 - [ ( methoxycarbonyl ) amino ] - 2 - phenylacetyl } - 4 - ( methoxymethyl ) - 2 - pyrrolidinyl ] - 1H - imidazol - 4 - yl } - 1 , 11 - dihydroisochromeno [4' , 3' : 6 , 7 ] naphtho [ 1 , 2-d ] imidazol - 2 - yl ) - 5 - methyl - 1 - pyrrolidinyl ] - 3 - methyl - 1 - oxo - 2 - butanyl } carbamate

Molecular Formula : C49H54N8O8

Molecular Weight : 883.02

Description : 

Velpatasvir is innovated by Gilead to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Velpatasvir is a Direct-Acting Antiviral (DAA) medication used together with Sofosbuvir. The mechanism of action is as a Breast Cancer Resistance Protein Inhibitor, and P-Glycoprotein Inhibitor, and Organic Anion Transporting Polypeptide 1B1 Inhibitor, and Organic Anion Transporting Polypeptide 1B3 Inhibitor, and Organic Anion Transporting Polypeptide 2B1 Inhibitor. It blocks NS5A, a protein necessary for hepatitis C virus replication assembly.

The drug might be protected by patents in some courtires or areas. We only sell it to non patent protected countries or areas. The sale to patent protection countries and areas is only for R & D purpose. The buyers should take all responsiblity of patent status in his countries or areas.

Competitive Advantage: Produced under cGMP conditions, support customers’ registrations.